Data from the literature usually present sporadic cases of peripheral myxomatous embolism with very good results of surgical treatment of ischemia, as well as the removal of a heart tumor. [31, 32] ...

Of the 360 patients in the study population, 38 had recurrent venous thromboembolism (10.6 percent) (deep-vein thrombosis in 24 and pulmonary embolism in 14). Of these 38 patients, 27 were men and ...

Veterinary Clinics of North America: Small Animal Practice. 2004 vol 34, 5: 1209-1226. doi: 10.1016/J.CVSM.2004.05.002.3 Keene, Bruce W et al. “ACVIM consensus guidelines for the diagnosis and ...

Pioneering device combines precision clot removal with autologous blood reinfusion to address unmet needs in PE treatment MENLO PARK, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, the ...

Joe P. Chauvapun, MD; Maciej Dryjski, MD, PhD Disclosures Vascular. 2005;13 (1):50-57.

For pt.I see ibid., vol.43, no.6, p.572-80 (1996). A theoretical and numerical study of the acoustic field intensity within a curved flow conduit having (1) diameter similar to the wavelength of the ...

Four hundred and ninety-nine surgically excised valves were examined for pathological evidence of myxomatous degeneration. Thirty-six valves (7%) had myxomatous degeneration as a major pathological ...

Penumbra has completed subject enrolment in the multi-centre, randomised controlled trial, STORM-PE, which assesses the computer-assisted vacuum thrombectomy (CAVT) using the company’s Lightning Flash ...

Penumbra has introduced Ruby XL System, the detachable embolisation coil, which has also received clearance from the US Food and Drug Administration (FDA). The system is tailored to aid physicians ...

June 5, 2025—Penumbra, Inc. announced the FDA clearance and launch of the Ruby XL system, part of the company’s Ruby portfolio of peripheral embolization products. According to Penumbra, the Ruby XL, ...